Centers for Medicare and Medicaid Services urged to adopt a carve-out on HIV antiretroviral therapies for the drug price negotiations under Medicare Part D, designed to protect people living with HIV/AIDS

WASHINGTON, DC, July 10, 2025 /24-7PressRelease/ — ADAP Advocacy has submitted public comments to the Centers for Medicare and Medicaid Services (CMS) regarding the proposed guidance for the Medicare Drug Price Negotiation Program (“Negotiation Program”), established under the Inflation Reduction Act (2022), calling for a carve-out on HIV antiretroviral therapies. ADAP Advocacy has requested this carve-out exemption due to the serious nature of the threat facing People Living with HIV/AIDS (PLWHA), should HIV medications be selected as part of the Negotiation Program.

Brandon M. Macsata, CEO of ADAP Advocacy, stated: “CMS is playing with fire if it targets HIV medications as part of its drug price negotiations, potentially putting the lives of PLWHA at risk. Patients who lose access to HIV medications may fall out of treatment entirely, placing them at risk of dying from opportunistic infections or having their HIV mutate to develop resistance to the medications used to achieve viral suppression. The cornerstone of the progress we’ve made in combating the HIV epidemic is adopting a ‘treatment as prevention’ approach, which saves money by preventing expensive health complications, as well as new HIV infections.”

Read the public comments:

Written testimony to the Centers for Medicare & Medicaid Services expressing concerns about the 2028 Medicare Drug Price Negotiation Program Draft Guidance, and asking for an HIV carve-out – June 25, 2025

To learn more about ADAP Advocacy, CMS’ drug price negotiations, or the requested HIV carve-out, please email info@adapadvocacy.org.

About ADAP Advocacy: ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.

—
For the original version of this press release, please visit 24-7PressRelease.com here